Last updated on February 2018

Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata


Brief description of study

This study will evaluate the safety and efficacy of CTP-543 in adult patients with chronic, moderate to severe alopecia areata.

Detailed Study Description

This is a double-blind, randomized, placebo-controlled multi-center study consisting of 2 cohorts to assess the safety and efficacy of CTP-543. Each Cohort will be initiated sequentially in ascending dose order. Subjects will be randomized to either an active dose of CTP-543 or placebo for a 24-week treatment period.

Clinical Study Identifier: NCT03137381

Contact Investigators or Research Sites near you

Start Over

Study Director

University of California, Irvine
Irvine, CA United States
  Connect »

Study Director

Contour Dermatology & Cosmetic Surgery Center
Rancho Mirage, CA United States
  Connect »

Study Director

Stanford University School of Medicine
Redwood City, CA United States
  Connect »

Study Director

Kaiser Permanente Northern California
San Francisco, CA United States
  Connect »

Study Director

Yale School of Medicine
New Haven, CT United States
  Connect »

Study Director

Northwestern University
Chicago, IL United States
  Connect »

Study Director

Minnesota Clinical Study Center
Fridley, MN United States
  Connect »

Study Director

Icahn School of Medicine at Mt. Sinai
New York, NY United States
  Connect »

Study Director

Columbia University
New York, NY United States
  Connect »

Study Director

Wake Forest University Health Sciences
Winston-Salem, NC United States
  Connect »

Study Director

Cleveland Clinic
Cleveland, OH United States
  Connect »

Study Director

Northwest Dermatology
Portland, OR United States
  Connect »

Study Director

Suzanne Bruce & Associates, PA
Houston, TX United States
  Connect »